Quince Therapeutics IncNASDAQ:QNCXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7857
- TODAY'S CHANGE (%)0.0057 (0.7308%)
- Bid / Lots0.7642/ 13
- Ask / Lots0.8600/ 40
- Open / Previous Close0.7530 / 0.7800
- Day Range
- 52 Week Range
- Volume38,524
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QNCX |
|---|---|---|
| 09:32 ET | 5011 | 0.753 |
| 09:36 ET | 900 | 0.78 |
| 09:38 ET | 100 | 0.82 |
| 09:41 ET | 3100 | 0.78 |
| 09:45 ET | 300 | 0.78 |
| 09:48 ET | 400 | 0.78 |
| 10:21 ET | 2500 | 0.79 |
| 10:24 ET | 100 | 0.79 |
| 10:28 ET | 250 | 0.790049 |
| 10:53 ET | 100 | 0.7907 |
| 11:58 ET | 2600 | 0.7867 |
| 12:18 ET | 226 | 0.78 |
| 12:38 ET | 100 | 0.79 |
| 02:20 ET | 100 | 0.78 |
| 02:26 ET | 2120 | 0.78 |
| 02:42 ET | 100 | 0.78 |
| 02:51 ET | 100 | 0.78 |
| 03:02 ET | 200 | 0.78 |
| 03:05 ET | 487 | 0.7825 |
| 03:07 ET | 100 | 0.78 |
| 03:09 ET | 100 | 0.78 |
| 03:14 ET | 1050 | 0.7803 |
| 03:16 ET | 5219 | 0.78 |
| 03:18 ET | 209 | 0.77505 |
| 03:21 ET | 100 | 0.77 |
| 03:25 ET | 509 | 0.7717 |
| 03:27 ET | 200 | 0.7713 |
| 03:32 ET | 400 | 0.7705 |
| 03:34 ET | 759 | 0.7752 |
| 03:36 ET | 280 | 0.77 |
| 03:50 ET | 9199 | 0.785 |
| 03:52 ET | 100 | 0.77 |
| 03:56 ET | 100 | 0.77 |
| 03:59 ET | 200 | 0.7857 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quince Therapeutics Inc | 33.7M | -1.0x | --- |
NeuroBo Pharmaceuticals Inc | 33.7M | -1.3x | --- |
Achilles Therapeutics PLC | 34.4M | -0.5x | --- |
LianBio | 32.4M | -0.4x | --- |
Xilio Therapeutics Inc | 35.4M | -0.4x | --- |
Acurx Pharmaceuticals Inc | 35.8M | -1.9x | --- |
Company Information
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.
Contact Information
- Headquarters
- 601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-910-5717
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Lamond
- President
- Charles Ryan
- Chief Executive Officer, Chief Medical Officer, Director
- Dirk Thye
- Chief Financial Officer, Chief Business Officer
- Brendan Hannah
- Lead Independent Director
- Una Ryan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.93 |
EPS | $-0.76 |
Book Value | $1.98 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
